Literature DB >> 33502584

[Brain metastases-Interdisciplinary approach towards a personalized treatment].

S Grau1,2, M Herling3,4, C Mauch5,4, N Galldiks6,4,7, H Golla8,4, M Schlamann9, A H Scheel10,4, E Celik11,4, M Ruge12,4, R Goldbrunner13,4.   

Abstract

The incidence, treatment and prognosis of patients with brain metastases have substantially changed during the last decades. While the survival time after diagnosis of cerebral metastases was on average a maximum of 3-6 months only 10 years ago, the survival time could be significantly improved due to novel surgical, radiotherapeutic and systemic treatment modalities. Only a few years ago, the occurrence of brain metastases led to a withdrawal from systemic oncological treatment and the exclusion of drug therapy studies and to a purely palliatively oriented treatment in the sense of whole brain radiation therapy (WBRT) with or without surgery. The increasing availability of targeted and immunomodulatory drugs as well as adapted radio-oncological procedures enable increasingly more personalized treatment approaches. The aim of this review article is to demonstrate the progress and complexity of the treatment of brain metastases in the context of modern comprehensive interdisciplinary concepts.

Entities:  

Keywords:  Brain metastases; Radiosurgery; Radiotherapy; Targeted treatment; Treatment monitoring

Mesh:

Year:  2021        PMID: 33502584     DOI: 10.1007/s00104-020-01344-y

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  41 in total

1.  Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Authors:  Diana S Y Abdulla; Matthias Scheffler; Vanessa Brandes; Maximilian Ruge; Sabine Kunze; Sabine Merkelbach-Bruse; Lucia Nogova; Sebastian Michels; Rieke Fischer; Richard Riedel; Reinhard Büttner; Thorsten Persigehl; Stefan Grau; Norbert Galldiks; Alexander Drzezga; Carsten Kobe; Jürgen Wolf
Journal:  Clin Lung Cancer       Date:  2018-11-05       Impact factor: 4.785

2.  Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.

Authors:  Cornelius Deuschl; Felix Nensa; Johannes Grueneisen; Thorsten D Poeppel; Lino M Sawicki; Philipp Heusch; Carolin Gramsch; Christoph Mönninghoff; Harald H Quick; Michael Forsting; Lale Umutlu; Marc Schlamann
Journal:  Acta Radiol       Date:  2016-12-14       Impact factor: 1.990

3.  Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Authors:  Garry Ceccon; Philipp Lohmann; Gabriele Stoffels; Natalie Judov; Christian P Filss; Marion Rapp; Elena Bauer; Christina Hamisch; Maximilian I Ruge; Martin Kocher; Klaus Kuchelmeister; Bernd Sellhaus; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

4.  Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery.

Authors:  Francesco Cicone; Giuseppe Minniti; Andrea Romano; Annalisa Papa; Claudia Scaringi; Francesca Tavanti; Alessandro Bozzao; Riccardo Maurizi Enrici; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

5.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

6.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Authors:  Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge
Journal:  Lancet Oncol       Date:  2017-07-04       Impact factor: 41.316

7.  Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.

Authors:  Marie A Bakitas; Tor D Tosteson; Zhigang Li; Kathleen D Lyons; Jay G Hull; Zhongze Li; J Nicholas Dionne-Odom; Jennifer Frost; Konstantin H Dragnev; Mark T Hegel; Andres Azuero; Tim A Ahles
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

8.  Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control.

Authors:  Clara Y H Choi; Steven D Chang; Iris C Gibbs; John R Adler; Griffith R Harsh; Robert E Lieberson; Scott G Soltys
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

9.  Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Authors:  Alexander Drilon; Salvatore Siena; Rafal Dziadziuszko; Fabrice Barlesi; Matthew G Krebs; Alice T Shaw; Filippo de Braud; Christian Rolfo; Myung-Ju Ahn; Jürgen Wolf; Takashi Seto; Byoung Chul Cho; Manish R Patel; Chao-Hua Chiu; Thomas John; Koichi Goto; Christos S Karapetis; Hendrick-Tobias Arkenau; Sang-We Kim; Yuichiro Ohe; Yu-Chung Li; Young K Chae; Christine H Chung; Gregory A Otterson; Haruyasu Murakami; Chia-Chi Lin; Daniel S W Tan; Hans Prenen; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; Robert C Doebele
Journal:  Lancet Oncol       Date:  2019-12-11       Impact factor: 41.316

10.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

Authors:  K A Ahmed; Y A Abuodeh; M I Echevarria; J A Arrington; D G Stallworth; C Hogue; A O Naghavi; S Kim; Y Kim; B G Patel; S Sarangkasiri; P A S Johnstone; S Sahebjam; N I Khushalani; P A Forsyth; L B Harrison; M Yu; A B Etame; J J Caudell
Journal:  Ann Oncol       Date:  2016-09-15       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.